Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU – Get Free Report) have received a consensus rating of “Hold” from the seven analysts that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation, one has assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $4.50.
Several equities analysts recently commented on CRBU shares. Wall Street Zen downgraded shares of Caribou Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, September 19th. Bank of America cut their price objective on shares of Caribou Biosciences from $6.00 to $5.00 and set a “buy” rating for the company in a report on Friday, August 14th. HC Wainwright lowered shares of Caribou Biosciences from a “buy” rating to a “neutral” rating in a research report on Thursday, October 8th. Leerink Partners cut shares of Caribou Biosciences from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $4.00 to $1.00 in a report on Wednesday, October 7th. Finally, Royal Bank Of Canada lowered Caribou Biosciences from an “outperform” rating to a “sector perform” rating and set a $1.00 target price on the stock. in a report on Wednesday, October 7th.
Get Our Latest Stock Analysis on Caribou Biosciences
Caribou Biosciences Stock Performance
Caribou Biosciences (NASDAQ:CRBU – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.01. The firm had revenue of $1.61 million during the quarter, compared to the consensus estimate of $1.60 million. Caribou Biosciences had a negative net margin of 1,085.00% and a negative return on equity of 102.74%. On average, sell-side analysts expect that Caribou Biosciences will post -0.94 EPS for the current year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the stock. CTC Alternative Strategies Ltd. bought a new stake in Caribou Biosciences in the first quarter worth approximately $29,000. Next Capital Management LLC bought a new position in shares of Caribou Biosciences during the 2nd quarter worth approximately $35,000. The Manufacturers Life Insurance Company bought a new position in shares of Caribou Biosciences during the 2nd quarter worth approximately $41,000. Spark Investment Management LLC bought a new position in shares of Caribou Biosciences during the 2nd quarter worth approximately $42,000. Finally, Sei Investments Co. acquired a new stake in shares of Caribou Biosciences during the 1st quarter worth approximately $59,000. Institutional investors own 77.51% of the company’s stock.
About Caribou Biosciences
Caribou Biosciences, Inc. is a clinical-stage biotechnology company developing genome-edited cell therapies for cancer and other serious diseases. Its work focuses on allogeneic, or donor-derived, CAR-T cell treatments designed to be manufactured for use by multiple patients. The company uses its chRDNA genome-editing platform, which combines CRISPR RNA with DNA components, to make targeted changes to cells. Its clinical programs include CAR-T candidates directed at targets such as CD19 and BCMA, which are being developed for certain blood cancers.
Further Reading
- Five stocks we like better than Caribou Biosciences
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Caribou Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caribou Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
